Journal ArticleDOI
The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)
Philip S. Helliwell,Philip S. Helliwell,Oliver FitzGerald,Jaap Fransen,Dafna D. Gladman,Gerald G Kreuger,Kristina Callis-Duffin,Neil McHugh,Philip J. Mease,Vibeke Strand,Robin Waxman,Valderílio Feijó Azevedo,Adriana Beltran Ostos,Sueli Carneiro,Alberto Cauli,Luis R Espinoza,John A. Flynn,Nada Hassan,Paul J. Healy,Eduardo Kerzberg,Yun Jong Lee,Ennio Lubrano,Antonio Marchesoni,Helena Marzo-Ortega,Giovanni Porru,Elvia G. Moreta,Peter Nash,Helena Raffayova,Roberto Ranza,Siba P. Raychaudhuri,Euthalia Roussou,Raphael Scarpa,Yeong Wook Song,Enrique R. Soriano,Paul P. Tak,Ilona Ujfalussy,Kurt de Vlam,Jessica A. Walsh +37 more
Reads0
Chats0
TLDR
Two new composite measures to assess disease activity in PsA have been developed by multiple linear regression and empirically, utilising physician-defined cut-offs for disease activity, and area under the receiver operating curves (AUC) were generally smaller.Abstract:
Objective To develop new composite disease activity indices for psoriatic arthritis (PsA). Methods Data from routine clinic visits at multiple centres were collected in a systematic manner. Data included all domains identified as important in randomised controlled trials in PsA. Decisions to change treatment were used as surrogates for high disease activity. New indices were developed by multiple linear regression (psoriatic arthritis disease activity score: PASDAS) and empirically, utilising physician-defined cut-offs for disease activity (arithmetic mean of desirability functions: AMDF). These were compared with existing composite measures: Composite Psoriatic arthritis Disease Activity Index (CPDAI), Disease Activity for PSoriatic Arthritis (DAPSA), and Disease Activity Score for rheumatoid arthritis (DAS28). Results 161/503 (32%) subjects had treatment changes. Although all measures performed well, compared with existing indices, PASDAS was better able to discriminate between high and low disease activity (area under receiver operating curves (ROC)) curve with 95% CI: PASDAS 0.773 (0.723, 0.822); AMDF 0.730 (0.680, 0.780); CPDAI 0.719 (0.668, 0.770); DAPSA 0.710 (0.654, 0.766); DAS28 0.736 (0.680, 0.792). All measures were able to discriminate between disease activity states in patients with oligoarthritis, although area under the receiver operating curves (AUC) were generally smaller. In patients with severe skin disease (psoriasis area and severity index >10) both nonparametric and AUC curve statistics were nonsignificant for all measures. Conclusions Two new composite measures to assess disease activity in PsA have been developed. Further testing in other datasets, including comparison with existing measures, is required to validate these instruments.read more
Citations
More filters
Indices for measurement of disease activity and therapeutic response in psoriatic arthritis. Part II: Composite indices, quality of life and global assessment of patient and physician.
A. Kopchev,S. Monov +1 more
TL;DR: A single composite index that includes all aforementioned points will allow assessment the whole disease spectrum with only one tool.
Journal ArticleDOI
Exploiting Signal Joint T Cell Receptor Excision Circle to Investigate the Impact of COVID-19 and Autoimmune Diseases on Age Prediction and Immunosenescence
Amina Farag,Taghrid Kharboush,Noha Hosni Ibrahim,Mohamed M. Darwish,Iman M. Fawzy,Hanaa Bayomy,Dina Saad Abdelmotaleb,Shaza A. Abdul Basset,Amal M. Abdel-Kareim,Mohammed Al mohaini,Inas A. Ahmed,Haidy mohammed Fakher +11 more
TL;DR: Signal joint T cell receptor excision circles (sjTRECs) are a promising marker for age estimation and immunosenescence in different ethnic groups as discussed by the authors . But several limitations are expected to overshadow their use as accurate markers for age prediction.
Journal ArticleDOI
A Needs-Based Rheumatologist Education Program on Treating to Target in Psoriatic Arthritis and Spondyloarthropathy: Insights and Challenges
Janet E. Pope,Linda Wang,Paul C Tingey,Angela Montgomery,Art Karasik,Pauline Boulos,Vandana Ahluwalia,Maggie Larché,Sara Haig,Nikhil Chopra,Gina Rohekar,Sherry Rohekar +11 more
TL;DR: This study did not show a significant change in behavior for rheumatologists who had education based on care gaps and needs assessment in psoriatic arthritis and spondyloarthropathy.
Proceedings ArticleDOI
AB0754 Comparison of composite indices tailored for psoriatic arthritis treated with csdmards and bdmards: a longitudinal observational study
TL;DR: Overall, the concordance between the indices ranging from slight to good was found, with patients in bDMARDs had a significantly low median DAPSA, cDAPSA and PASDAS score than patients treated with cs DMARDs.
References
More filters
Journal ArticleDOI
Measurement of patient outcome in arthritis.
TL;DR: A structure for representation of patient outcome is presented, together with a method for outcome measurement and validation of the technique in rheumatoid arthritis, and these techniques appear extremely useful for evaluation of long term outcome of patients with rheumatic diseases.
Journal ArticleDOI
Severe psoriasis--oral therapy with a new retinoid.
T. Fredriksson,Ulf Pettersson +1 more
TL;DR: Ro 10--9359 proved to be an extremely potent antipsoriatic drug and a more than 90% reduction of psoriatic lesions could be seen in 10 patients out of 20 after 4-8 weeks of treatment.
Journal ArticleDOI
Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria
A.M. van Gestel,M.L.L. Prevoo,M.A. van 't Hof,M. H. Van Rijswijk,L. B. A. Van De Putte,P.L.C.M. van Riel +5 more
TL;DR: EULAR response criteria showed better construct and discriminant validity than did the ACR and the WHO/ILAR response criteria for RA and the World Health Organization and International League Against Rheumatism criteria.
Journal ArticleDOI
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
TL;DR: Etanercept offers patients with psoriatic arthritis and psoriasis a new therapeutic option for control of their disease.
Journal Article
Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index
TL;DR: Five clinical measurements provide a composite index (BASMI) and define disease status in AS, which is quick, reproducible and sensitive to change across the disease spectrum.
Related Papers (5)
Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
Laure Gossec,Josef S Smolen,Sofia Ramiro,M. de Wit,Maurizio Cutolo,Maxime Dougados,Paul Emery,Robert Landewé,Sue Oliver,Daniel Aletaha,Neil Betteridge,Jürgen Braun,G.-R. Burmester,Juan D. Cañete,Nemanja Damjanov,Oliver FitzGerald,Emma Haglund,P S Helliwell,Tore K Kvien,Rik Lories,Thomas A. Luger,Mara Maccarone,Helena Marzo-Ortega,Dennis McGonagle,Iain B. McInnes,I. Olivieri,Karel Pavelka,Georg Schett,Joachim Sieper,F. Van den Bosch,Douglas J. Veale,Jürgen Wollenhaupt,Angela Zink,D. van der Heijde +33 more
Treatment recommendations for psoriatic arthritis
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
Laura C. Coates,Arthur Kavanaugh,Philip J. Mease,Enrique R. Soriano,Maria Laura Acosta-Felquer,April W. Armstrong,Wilson Bautista-Molano,Wolf-Henning Boehncke,Willemina Campbell,Alberto Cauli,Luis R. Espinoza,Oliver FitzGerald,Dafna D. Gladman,Alice B. Gottlieb,Philip S. Helliwell,M. Elaine Husni,Thorvardur Jon Love,Ennio Lubrano,Neil McHugh,Peter Nash,Alexis Ogdie,Ana Maria Orbai,Andrew Parkinson,Denis O'Sullivan,Cheryl F. Rosen,Sergio Schwartzman,Evan L. Siegel,Sergio Toloza,William Tuong,Christopher T. Ritchlin +29 more